Supplier
Putnam General Hospital Authority
Putnam General Hospital Authority was paid $3.28M by Medicaid between Jan 2018 and Dec 2024, across 90 billing codes. Its largest line is 99282, Emergency department visit for the evaluation and management, low to moderate severity — 36% of everything it billed.
33Billing provider infoPUTNAM GENERAL HOSPITAL AUTHORITY
EATONTON, GA 31024
EATONTON, GA 31024
33aNPI1184810509assigned 09/19/2007
33bProvider typeOxygen Equipment & Supplies (DME)
28Total paid$3.28M
24GClaims111,346
24DCodes billed90
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Oxygen Equipment & Supplies (DME) providers in Georgia
Rank by total paid#1 of 6
Median peer was paid$65K
This provider vs. median50×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,950 | $460K | |
| 2019 | 19,233 | $485K | |
| 2020 | 11,072 | $321K | |
| 2021 | 16,055 | $451K | |
| 2022 | 18,421 | $585K | |
| 2023 | 18,454 | $597K | |
| 2024incomplete | 11,161 | $383K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 36% | 10,633 | 9,089 | $1.18M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 4,826 | 4,234 | $528K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.8% | 3,142 | 2,265 | $257K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.8% | 1,852 | 1,647 | $223K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.7% | 1,329 | 1,173 | $121K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.9% | 860 | 780 | $94K |
| 0240U | 2.6% | 953 | 800 | $86K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 731 | 510 | $83K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 3,513 | 2,425 | $78K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 1,869 | 1,568 | $54K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 1,470 | 1,130 | $48K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.3% | 2,849 | 2,379 | $42K |
78 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.1% | 248 | $36K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,064 | $32K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 140 | $32K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,297 | $31K |
| 80053 | Comprehensive metabolic panel | <1% | 7,035 | $30K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,008 | $30K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,664 | $26K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 257 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,185 | $17K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,026 | $15K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 990 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 447 | $14K |
| 84484 | <1% | 2,775 | $12K | |
| 87430 | <1% | 1,510 | $12K | |
| J3490 | Unclassified drugs | <1% | 3,475 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,124 | $10K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 36 | $9K |
| E0601 | Continuous positive airway pressure (cpap) device | <1% | 713 | $9K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 426 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 587 | $8K |
| G0378 | Hospital observation service, per hour | <1% | 63 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 354 | $7K |
| 82553 | <1% | 1,240 | $7K | |
| 81025 | <1% | 1,603 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,216 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,742 | $6K |
| 81001 | <1% | 3,876 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,413 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 402 | $4K |
| 83880 | <1% | 333 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 601 | $4K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 427 | $4K |
| 83690 | <1% | 1,188 | $4K | |
| 87070 | <1% | 639 | $4K | |
| 82550 | <1% | 1,450 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 37 | $2K |
| 85027 | <1% | 836 | $2K | |
| 94664 | <1% | 235 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,367 | $2K |
| 87400 | <1% | 233 | $2K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 16 | $2K |
| 80061 | Lipid panel | <1% | 269 | $2K |
| 87631 | <1% | 33 | $2K | |
| 83735 | <1% | 869 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 130 | $1K |
| 87077 | <1% | 208 | $1K | |
| 85379 | <1% | 201 | $1K | |
| A7038 | Filter, disposable, used with positive airway pressure device | <1% | 1,101 | $971.75 |
| 82150 | <1% | 265 | $703.14 | |
| 85730 | <1% | 226 | $698.11 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 34 | $640.82 |
| A7037 | Tubing used with positive airway pressure device | <1% | 141 | $613.82 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 37 | $573.27 |
| 87807 | <1% | 61 | $551.44 | |
| 97162 | <1% | 23 | $544.90 | |
| 87040 | <1% | 79 | $480.59 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 321 | $434.23 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,773 | $375.21 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 195 | $362.65 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 63 | $323.47 |
| 73562 | <1% | 23 | $322.54 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 60 | $297.63 |
| 83605 | <1% | 36 | $248.13 | |
| 85610 | <1% | 216 | $230.09 | |
| 85007 | <1% | 263 | $211.17 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 26 | $184.54 |
| 87186 | <1% | 26 | $178.41 | |
| 80305 | <1% | 262 | $174.32 | |
| 81003 | <1% | 236 | $169.61 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $145.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 121 | $92.69 |
| A7035 | Headgear used with positive airway pressure device | <1% | 15 | $60.96 |
| 87088 | <1% | 40 | $59.62 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $40.61 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 12 | $14.03 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 75 | $7.97 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 43 | $4.69 |
| A9270 | Non-covered item or service | 0% | 2,530 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCULBERSON, ANITA (REVENUE CYCLE DIRECTOR)